Antifungal therapy in children: new topics and prospects;Antifongiques systémiques en pédiatrie : actualités et perspectives

Archives de Pediatrie

Volumn 14, Issue 1, 2007, Pages 1-3

  Le Guyader, N ^a   Tabone, M D ^a   Leverger, G ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antifungal therapy; Child

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHILDHOOD DISEASE; HUMAN; IMMUNE DEFICIENCY; MYCOSIS;

ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT;

EID: 33846009444     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2006.11.004     Document Type: Article

References (19)

1. Grigull L., Beier R., Schrauder A., et al. Invasive fungal infections are responsible for one fifth of the infectious deaths in children with ALL. Mycoses 46 (2003) 441-446
2. Zaoutis T.E., Heydon K., Chu J.H., et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117 (2006) e711-e716
3. Pellegrino B., Le Guyader N., Thien V., et al. Infections candidosiques sévères chez le patient neutropénique en oncohématologie pédiatrique. Arch. Pediatr. 10 (2003) 575s-581s
4. Aujard Y., Farnoux C., Lefevre S., et al. Infections néonatales à candida. Arch. Pediatr. 10 Suppl 5 (2003) 569s-574s
5. Gray J., Gossain S., and Morris K. Three-year survey of bacteremia and fungemia in a pediatric intensive care unit. Pediatr. Infect. Dis. J. 20 (2001) 416-421
6. Autret-Leca E., Bensouda-Grimaldi L., Le Guellec C., et al. L'enfant et les médicaments : application à la prescription en pédiatrie. Arch. Pediatr. 13 (2006) 181-185
7. Treluyer J.M., and Pons G. Quoi de neuf en pharmacologie pédiatrique ?. Arch. Pediatr. 7 (2000) 1330-1338
8. Walsh T.J., Karlsson M.O., Driscoll T., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48 (2004) 2166-2172
9. Smith J., Safdar N., Knasinski V., et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50 (2006) 1570-1572
10. Walsh T.J., Adamson P.C., Seibel N.L., et al. Pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49 (2005) 4536-4545
11. Odio C.M., Araya R., Pinto L.E., et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23 (2004) 1093-1097
12. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340 (1999) 764-771
13. Wingard J.R., White M.H., Anaissie E., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31 (2000) 1155-1163
14. Wiley J.M., Seibel N.L., and Walsh T.J. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr. Infect. Dis. J. 24 (2005) 167-174
15. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347 (2002) 408-415
16. Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21 (2002) 240-248
17. Groll A.H., Attarbaschi A., Schuster F.R., et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J. Antimicrob. Chemother. 57 (2006) 527-535
18. Arrieta A, Telles Filho F, Berezin E, et al. for the micafungin invasive candidiasis study group. A randomized, double blind trial comparing micafungin and liposomal amphotericin B in pediatric patients with invasive candidiasis. International Conference on Antimicrobial Agents and Chemotherapy, 2006, 46, Abs M-1308b.
19. Cesaro S., Toffolutti T., Messina C., et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur. J. Haematol. 73 (2004) 50-55